Bruce Freimark

Bruce Freimark, Ph.D. has over 25 years of experience in the field of biotechnology and pharmaceuticals. Currently, they hold the position of Senior Director of Immuno-Oncology Research at Pulse Biosciences, Inc. Bruce'swork focuses on the development and evaluation of immuno-oncology products.

Prior to joining Pulse Biosciences, Dr. Freimark worked at Peregrine Pharmaceuticals from 2006 to 2017. There, they served as a Research Director in Preclinical Oncology, overseeing the evaluation of immuno-oncology products using animal tumor models. Additionally, they led the Tumor Imaging Program.

From 2001 to 2006, Dr. Freimark worked at CancerVax Corporation as the Director of Molecular and Protein Biology. In this role, they managed a team of scientists and was responsible for conducting research studies, writing technical reports, and developing patentable concepts and scientific data.

At Nexell Therapeutics, Dr. Freimark served as the Director of Molecular Biology in 1999-2000. Bruce managed a research budget and supervised research activities.

Earlier in their career, Dr. Freimark worked at GeneMedicine/Valentis as a Group Leader, managing a team of scientists and researchers.

Overall, Dr. Bruce Freimark has a vast experience in molecular and protein biology, preclinical oncology, and immuno-oncology research, holding various leadership positions in both pharmaceutical and biotechnology companies.

Bruce Freimark, Ph.D. holds a Bachelor's degree in Biology from Wittenberg University. Bruce completed a Post-Doctoral Fellowship in Molecular Immunology at Scripps Clinic and Research Foundation. Bruce also obtained a Ph.D. in Pathology from the University at Buffalo.